View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDanCann Pharma 将来の成長Future 基準チェック /06現在、 DanCann Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.お知らせ • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.お知らせ • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.お知らせ • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.お知らせ • Dec 20Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025Dancann Pharma A/S provided revenue guidance for the financial year 2025. For the year, the company targets a revenue growth exceeding 300%, and with that, attain the breakeven point by the year 2025.Breakeven Date Change • Oct 04Forecast to breakeven in 2024The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 73% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • May 21Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot ProgrammeDanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms.お知らせ • Apr 24+ 1 more updateDanCann Pharma A/S to Report Q3, 2025 Results on Oct 27, 2025DanCann Pharma A/S announced that they will report Q3, 2025 results at 6:00 PM, Central European Standard Time on Oct 27, 2025お知らせ • Apr 11DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025お知らせ • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.お知らせ • Mar 28DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025お知らせ • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.お知らせ • Dec 11DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of DirectorsDanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors.お知らせ • Oct 31DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024New Risk • Aug 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr.15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.15m free cash flow). Share price has been highly volatile over the past 3 months (38% average weekly change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€1.61m market cap, or US$1.77m). Minor Risk Revenue is less than US$5m (kr.8.2m revenue, or US$1.2m).Reported Earnings • Aug 15Second quarter 2024 earnings released: kr.0.004 loss per share (vs kr.0.05 loss in 2Q 2023)Second quarter 2024 results: kr.0.004 loss per share (improved from kr.0.05 loss in 2Q 2023). Revenue: kr.3.86m (up 38% from 2Q 2023). Net loss: kr.633.0k (loss narrowed 79% from 2Q 2023).お知らせ • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.お知らせ • Aug 01DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024お知らせ • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.Reported Earnings • Jun 04First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.702.0k (down 31% from 1Q 2023). Net loss: kr.2.60m (loss narrowed 26% from 1Q 2023).お知らせ • May 03DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024お知らせ • May 01DanCann Pharma A/S, Annual General Meeting, May 30, 2024DanCann Pharma A/S, Annual General Meeting, May 30, 2024.お知らせ • Apr 04Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024Reported Earnings • Mar 01Full year 2023 earnings released: kr.0.13 loss per share (vs kr.0.25 loss in FY 2022)Full year 2023 results: kr.0.13 loss per share (improved from kr.0.25 loss in FY 2022). Revenue: kr.7.15m (flat on FY 2022). Net loss: kr.12.3m (loss narrowed 23% from FY 2022).お知らせ • Dec 20Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025Dancann Pharma A/S provided revenue guidance for the financial year 2025. For the year, the company targets a revenue growth exceeding 300%, and with that, attain the breakeven point by the year 2025.Reported Earnings • Dec 01Third quarter 2023 earnings released: kr.0.033 loss per share (vs kr.0.096 loss in 3Q 2022)Third quarter 2023 results: kr.0.033 loss per share. Revenue: kr.1.86m (down 30% from 3Q 2022). Net loss: kr.2.75m (loss widened 1.3% from 3Q 2022).Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.2.80m (up 154% from 2Q 2022). Net loss: kr.3.02m (loss narrowed 35% from 2Q 2022).Board Change • Aug 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Jun 09New major risk - Revenue and earnings growthEarnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 57% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Revenue is less than US$1m (kr.6.6m revenue, or US$951k). Market cap is less than US$10m (€3.20m market cap, or US$3.45m).お知らせ • Jun 02Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product ApprovalDanCann Pharma A/S announced the successful QC analysis of its pre-validation batches. The Company has confirmed that all batches have been tested in accordance with European (German and Danish) standards, meeting the required specifications and further advancing the approval process. As part of its commitment to ensuring the higher standards of quality and compliance, DanCann Pharma conducted comprehensive testing of its pre-validation batches. The testing process followed European (German and Danish) products. The results of the analysis have demonstrated that all pre-validation batches have successfully met the rigorous specifications set by European (German and Danish) standards. This achievement underscores DanCann Pharma's unwavering dedication to producing safe and effective therapeutic cannabinoids in line with the higher regulatory and industry requirements.お知らせ • May 31Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board MemberDancann Pharma A/S appointed Louise Bertelsen Forman as a new additional board member.Reported Earnings • May 14Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.7.19m (up kr.6.32m from FY 2021). Net loss: kr.16.1m (loss widened 37% from FY 2021). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.Board Change • Apr 08No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 15No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Feb 13Dancann Pharma A/S to Report Fiscal Year 2022 Results on Feb 27, 2023Dancann Pharma A/S announced that they will report fiscal year 2022 results on Feb 27, 2023お知らせ • Jan 04DanCann Pharma A/S Appoints Peter Søndergaard as CFODanCann Pharma A/S announces that the Company has appointed Peter Søndergaard as new Chief Financial Officer ('CFO'). Peter Søndergaard, who holds a Master of Science in Strategy and Management, has more than 15 years of experience from C-level employment in production and sales companies. At DanCann Pharma, Peter Søndergaard will lead the finance function in the growing organization, which consists of DanCann Pharma A/S and the subsidiary CannGros ApS. He will be responsible for developing and implementing relevant financial management tools adapted to the individual business areas in collaboration with the executive management team, of which he will be a part together with CEO Jeppe Krog Rasmussen, COO Sarah Mai Holm and CEO in the subsidiary CannGros, Louise Conradsen. Peter Søndergaard has joined the Company from the beginning of January together with two more new colleagues. DanCann Pharma has 18 employees from January 2023.お知らせ • Dec 03DanCann Pharma A/S Receives EU-GMP Certification for Its Manufacturing Facility Biotech Pharm1DanCann Pharma A/S announced that the Company will obtain its EU-GMP certification of its facility Biotech Pharm1 from the Danish Medicines Agency and subsequently admitted under the Danish Pilot Programme for the manufacturing of cannabis bulk. At DanCann Pharma in Ansager the Danish Medicines Agency has successfully completed their inspection of the Company's manufacturing Facility with no major deviations. The inspection was carried out over the days from Tuesday November 29 and Wednesday November 30, after which the Company was notified of the approval. This means that the Company with the EU-GMP certification in hand will be officially admitted under the Danish Pilot Programme with medical cannabis, where the Facility until now has been categorized under the Development Scheme, which is a section under the actual Pilot Programme. A formal report is being prepared, which the Danish Medicines Agency expects to forward to DanCann Pharma before the end of 2022. The Company will now initiate its first commercial batches from the Facility, where the Company must work in parallel with its Product Quality Review ("PQR"), which is the validation of the first batches, so the Company can prove it can bring standardized products to market, manufactured under procedure and protocols, as well as within specification, and to do this over time - initially assessed on its first three (3) batches. This will ultimately form the basis for the Company being approved to release its products in May. This (the release of products) requires an additional inspection which is expected to take place in March/April 2023. DanCann Pharma expects to ship its first batch to WEECO Pharma GmbH in May 2023.Board Change • Nov 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 26Dancann Pharma A/S to Report Q3, 2022 Results on Nov 04, 2022Dancann Pharma A/S announced that they will report Q3, 2022 results on Nov 04, 2022Breakeven Date Change • Oct 04Forecast to breakeven in 2024The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 73% is required to achieve expected profit on schedule.Board Change • Oct 04No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Sep 23DanCann Pharma A/S Announces Board of Directors AppointmentsDanCann Pharma A/S announced at the EGM the Board of Directors appointed Alexander Schoeneck and Jeppe Krog Rasmussen to the Board of Directors. Jeppe Krog Rasmussen is Born in 1995. Founder and Chief Executive Officer (CEO) in DanCann Pharma A/S since the Company's foundation back in March 2018. Jeppe Krog Rasmussen is responsible for the strategic direction and operational execution of all processes relevant to DanCann Pharma. He was a member of the Company's Board of Directors during the years 2020-2022. Jeppe Krog Rasmussen is a serial entrepreneur with strong experience from starting and building companies as well as working and investing in complex industries. In addition to DanCann Pharma Jeppe Krog Rasmussen runs his investment company, XIGNOTUS CAPITAL ApS, where he manages his investment portfolio. Alexander Born in 1983. Professional investor since 2016. Alexander Schoeneck is the chairman of the board in JEQ Capital, a fund with focus on small companies in an early stage. Alexander is also a board member in Corpura Fondkommission, EllWee AB (listed on Nasdaq First North), JEQ Capital Holding, Corpura Holding, Campingstugan Invest, Black Lion Media Group AB, Glassaparken AB and JJV Invest AB. Alexander has been part of DanCann Pharma's journey from the beginning and has always worked as an advisor for founder and CEO Jeppe Krog Rasmussen. Alexander has great experience when it comes to the financial markets, corporate finance and investor relations.お知らせ • Sep 21Dancann Pharma A/S Announces Board ChangesDancann Pharma A/S announced that Magnus Østergaard Dahlmann and Per Wester resign from the Board of Directors with effect from 20 September 2022. As a consequence hereof, the Board of Directors proposed election of: Jeppe Krog Rasmussen, Smaragdvej 9, 9 tv. 7100 Vejle Denmark. and Alexander Schoeneck Runnvägen 24, 79153 Falun, Sweden. as new board members (in replacement of Magnus Østergaard Dahlmann and Per Wester). Jeppe Krog Rasmussen and Alexander Schoeneck were elected unanimously and with all votes cast. As from the extraordinary general meeting, the members of the Board of Directors are Carsten Trads, Christian Carlsen, Tue Østergaard, Jeppe Krog Rasmussen and Alexander Schoeneck. The Board of Directors noted that Carsten Trads continues as chairman, and that Christian Carlsen continues as vice-chairman.Reported Earnings • Sep 02Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr.4.64m (loss widened 161% from 2Q 2021). Over the next year, revenue is forecast to grow 522%, compared to a 6.9% growth forecast for the Pharmaceuticals industry in Germany.Board Change • Aug 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 16Dancann Pharma A/S Appoints Charlotte Hagedorn Jørgensen as New Head of Quality AssuranceDanCann Pharma A/S announced the employment of Charlotte Hagedorn Jørgensen as Head of Quality Assurance at DanCann Pharma A/S. Charlotte Hagedorn Jørgensen joins the DanCann Pharma team as the Company's Head of Quality Assurance. She is an experienced quality management professional and will oversee implementing relevant quality systems according to global standards such as GMP and GDP. Charlotte Hagedorn Jørgensen has a proven track record within Quality Assurance and joins DanCann Pharma from a job as qualified person at Mezina A/S. She has more than 20 years of experience from working with GMP, GDP and general pharmaceutical issues. Charlotte Hagedorn Jørgensen has on several occasions been the driving force behind startups, which have developed into international successes within the pharma-industry such as 2Care4 ApS. Her entrepreneurial spirit and huge ambitions to make a difference will be a significant asset for DanCann Pharma. She is looking forward to her participation in the development of DanCann Pharma as an important contributor on the Danish and international markets.Breakeven Date Change • Jun 10Forecast to breakeven in 2024The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 71% is required to achieve expected profit on schedule.Board Change • May 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 12Dancann Pharma A/S Appoints Martin Vedel Ernst as New Chief Financial OfficerDancann Pharma A/S announced that the Company appoints Martin Vedel Ernst as new Chief Financial Officer. In the future, DanCann Pharma's financial tasks will be handled by Martin Vedel Ernst. Martin Ernst has an educational background as Cand. Merc. Aud. from Copenhagen Business School and business experience from jobs as accountant at Deloitte and as Group Financial Controller at Vestas.Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Christian Carlsen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 28Dancann Pharma A/S Elects Tue Østergaard as New Board MemberDancann Pharma A/S at the annual general meeting held on April 27, 2022 elected Tue Østergaard as a new board member.お知らせ • Mar 29DanCann Pharma A/S Appoints Sarah Mai Lykke-Kjeldsen as New Chief Operating Officer, Effective 1 April 2022DanCann Pharma A/S announced that the company has appointed Sarah Mai Lykke-Kjeldsen as new Chief Operating Officer. Sarah Mai Lykke-Kjeldsen will join DanCann Pharma on 1 April 2022.お知らせ • Mar 23Dancann Pharma A/S to Report Fiscal Year 2021 Results on Apr 13, 2022Dancann Pharma A/S announced that they will report fiscal year 2021 results on Apr 13, 2022お知らせ • Feb 09Dancann Pharma A/S Has Submitted Application to the Danish Medicines Agency for Eu-GMP-Approval for Biotech PharmDanCann Pharma A/S announced that the Company submitted its application for EU-GMP-approval to the Danish Medicines Agency. Biotech Pharm1 is built on best practices from the pharmaceutical industry in combination with advanced environmentally controlled manufacturing technology and vertical cultivation. This means that the selected geneticists are developed in multi-storey systems without the use of soil or other media, but with a specially developed system that adds the required amount of fluid and nutrients.Breakeven Date Change • Jun 04Forecast to breakeven in 2025The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests the company will make a profit of kr.1.00m in 2025. Average annual earnings growth of 13% is required to achieve expected profit on schedule. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、DanCann Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:DAN0 - アナリストの将来予測と過去の財務データ ( )DKK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20254-10-3-3N/A6/30/20254-11-5-5N/A3/31/20257-8-7-7N/A12/31/20247-8-5-5N/A9/30/20248-58-5-5N/A6/30/20248-57-11-11N/A3/31/20247-62-12-10N/A12/31/20237-62-16-12N/A9/30/20237-16-20-14N/A6/30/20238-16-18-11N/A3/31/20237-16-18-11N/A12/31/20227-16-20-12N/A9/30/20227-15-39-16N/A6/30/20224-15-40-15N/A3/31/20224-13-43-16N/A12/31/20212-12-44-12N/A9/30/20211-9-39-13N/A3/31/20210-6N/AN/AN/A12/31/2020N/A-4-26-8N/A9/30/20200-2N/AN/AN/A12/31/201900-10N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DAN0の予測収益成長が 貯蓄率 ( 1.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: DAN0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: DAN0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: DAN0の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: DAN0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DAN0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/27 11:59終値2026/01/12 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DanCann Pharma A/S 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Markus AugustssonCarlsquare ABJonatan AnderssonCarlsquare ABFredrik NilssonCarlsquare AB
お知らせ • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.
お知らせ • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.
お知らせ • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.
お知らせ • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.
お知らせ • Dec 20Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025Dancann Pharma A/S provided revenue guidance for the financial year 2025. For the year, the company targets a revenue growth exceeding 300%, and with that, attain the breakeven point by the year 2025.
Breakeven Date Change • Oct 04Forecast to breakeven in 2024The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
お知らせ • May 21Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot ProgrammeDanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms.
お知らせ • Apr 24+ 1 more updateDanCann Pharma A/S to Report Q3, 2025 Results on Oct 27, 2025DanCann Pharma A/S announced that they will report Q3, 2025 results at 6:00 PM, Central European Standard Time on Oct 27, 2025
お知らせ • Apr 11DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025
お知らせ • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.
お知らせ • Mar 28DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025
お知らせ • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.
お知らせ • Dec 11DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of DirectorsDanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors.
お知らせ • Oct 31DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024
New Risk • Aug 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr.15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.15m free cash flow). Share price has been highly volatile over the past 3 months (38% average weekly change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Market cap is less than US$10m (€1.61m market cap, or US$1.77m). Minor Risk Revenue is less than US$5m (kr.8.2m revenue, or US$1.2m).
Reported Earnings • Aug 15Second quarter 2024 earnings released: kr.0.004 loss per share (vs kr.0.05 loss in 2Q 2023)Second quarter 2024 results: kr.0.004 loss per share (improved from kr.0.05 loss in 2Q 2023). Revenue: kr.3.86m (up 38% from 2Q 2023). Net loss: kr.633.0k (loss narrowed 79% from 2Q 2023).
お知らせ • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.
お知らせ • Aug 01DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024
お知らせ • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.
Reported Earnings • Jun 04First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.702.0k (down 31% from 1Q 2023). Net loss: kr.2.60m (loss narrowed 26% from 1Q 2023).
お知らせ • May 03DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024
お知らせ • May 01DanCann Pharma A/S, Annual General Meeting, May 30, 2024DanCann Pharma A/S, Annual General Meeting, May 30, 2024.
お知らせ • Apr 04Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024
Reported Earnings • Mar 01Full year 2023 earnings released: kr.0.13 loss per share (vs kr.0.25 loss in FY 2022)Full year 2023 results: kr.0.13 loss per share (improved from kr.0.25 loss in FY 2022). Revenue: kr.7.15m (flat on FY 2022). Net loss: kr.12.3m (loss narrowed 23% from FY 2022).
お知らせ • Dec 20Dancann Pharma A/S Provides Revenue Guidance for the Financial Year 2025Dancann Pharma A/S provided revenue guidance for the financial year 2025. For the year, the company targets a revenue growth exceeding 300%, and with that, attain the breakeven point by the year 2025.
Reported Earnings • Dec 01Third quarter 2023 earnings released: kr.0.033 loss per share (vs kr.0.096 loss in 3Q 2022)Third quarter 2023 results: kr.0.033 loss per share. Revenue: kr.1.86m (down 30% from 3Q 2022). Net loss: kr.2.75m (loss widened 1.3% from 3Q 2022).
Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.2.80m (up 154% from 2Q 2022). Net loss: kr.3.02m (loss narrowed 35% from 2Q 2022).
Board Change • Aug 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Jun 09New major risk - Revenue and earnings growthEarnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 57% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Revenue is less than US$1m (kr.6.6m revenue, or US$951k). Market cap is less than US$10m (€3.20m market cap, or US$3.45m).
お知らせ • Jun 02Dancann Pharma A/S' Pre-Validation Batches Meets European Standards, Paving the Path for Final Product ApprovalDanCann Pharma A/S announced the successful QC analysis of its pre-validation batches. The Company has confirmed that all batches have been tested in accordance with European (German and Danish) standards, meeting the required specifications and further advancing the approval process. As part of its commitment to ensuring the higher standards of quality and compliance, DanCann Pharma conducted comprehensive testing of its pre-validation batches. The testing process followed European (German and Danish) products. The results of the analysis have demonstrated that all pre-validation batches have successfully met the rigorous specifications set by European (German and Danish) standards. This achievement underscores DanCann Pharma's unwavering dedication to producing safe and effective therapeutic cannabinoids in line with the higher regulatory and industry requirements.
お知らせ • May 31Dancann Pharma A/S Appoints Louise Bertelsen Forman as A New Additional Board MemberDancann Pharma A/S appointed Louise Bertelsen Forman as a new additional board member.
Reported Earnings • May 14Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.7.19m (up kr.6.32m from FY 2021). Net loss: kr.16.1m (loss widened 37% from FY 2021). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany.
Board Change • Apr 08No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 15No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 13Dancann Pharma A/S to Report Fiscal Year 2022 Results on Feb 27, 2023Dancann Pharma A/S announced that they will report fiscal year 2022 results on Feb 27, 2023
お知らせ • Jan 04DanCann Pharma A/S Appoints Peter Søndergaard as CFODanCann Pharma A/S announces that the Company has appointed Peter Søndergaard as new Chief Financial Officer ('CFO'). Peter Søndergaard, who holds a Master of Science in Strategy and Management, has more than 15 years of experience from C-level employment in production and sales companies. At DanCann Pharma, Peter Søndergaard will lead the finance function in the growing organization, which consists of DanCann Pharma A/S and the subsidiary CannGros ApS. He will be responsible for developing and implementing relevant financial management tools adapted to the individual business areas in collaboration with the executive management team, of which he will be a part together with CEO Jeppe Krog Rasmussen, COO Sarah Mai Holm and CEO in the subsidiary CannGros, Louise Conradsen. Peter Søndergaard has joined the Company from the beginning of January together with two more new colleagues. DanCann Pharma has 18 employees from January 2023.
お知らせ • Dec 03DanCann Pharma A/S Receives EU-GMP Certification for Its Manufacturing Facility Biotech Pharm1DanCann Pharma A/S announced that the Company will obtain its EU-GMP certification of its facility Biotech Pharm1 from the Danish Medicines Agency and subsequently admitted under the Danish Pilot Programme for the manufacturing of cannabis bulk. At DanCann Pharma in Ansager the Danish Medicines Agency has successfully completed their inspection of the Company's manufacturing Facility with no major deviations. The inspection was carried out over the days from Tuesday November 29 and Wednesday November 30, after which the Company was notified of the approval. This means that the Company with the EU-GMP certification in hand will be officially admitted under the Danish Pilot Programme with medical cannabis, where the Facility until now has been categorized under the Development Scheme, which is a section under the actual Pilot Programme. A formal report is being prepared, which the Danish Medicines Agency expects to forward to DanCann Pharma before the end of 2022. The Company will now initiate its first commercial batches from the Facility, where the Company must work in parallel with its Product Quality Review ("PQR"), which is the validation of the first batches, so the Company can prove it can bring standardized products to market, manufactured under procedure and protocols, as well as within specification, and to do this over time - initially assessed on its first three (3) batches. This will ultimately form the basis for the Company being approved to release its products in May. This (the release of products) requires an additional inspection which is expected to take place in March/April 2023. DanCann Pharma expects to ship its first batch to WEECO Pharma GmbH in May 2023.
Board Change • Nov 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 26Dancann Pharma A/S to Report Q3, 2022 Results on Nov 04, 2022Dancann Pharma A/S announced that they will report Q3, 2022 results on Nov 04, 2022
Breakeven Date Change • Oct 04Forecast to breakeven in 2024The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Board Change • Oct 04No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Carsten Trads is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 23DanCann Pharma A/S Announces Board of Directors AppointmentsDanCann Pharma A/S announced at the EGM the Board of Directors appointed Alexander Schoeneck and Jeppe Krog Rasmussen to the Board of Directors. Jeppe Krog Rasmussen is Born in 1995. Founder and Chief Executive Officer (CEO) in DanCann Pharma A/S since the Company's foundation back in March 2018. Jeppe Krog Rasmussen is responsible for the strategic direction and operational execution of all processes relevant to DanCann Pharma. He was a member of the Company's Board of Directors during the years 2020-2022. Jeppe Krog Rasmussen is a serial entrepreneur with strong experience from starting and building companies as well as working and investing in complex industries. In addition to DanCann Pharma Jeppe Krog Rasmussen runs his investment company, XIGNOTUS CAPITAL ApS, where he manages his investment portfolio. Alexander Born in 1983. Professional investor since 2016. Alexander Schoeneck is the chairman of the board in JEQ Capital, a fund with focus on small companies in an early stage. Alexander is also a board member in Corpura Fondkommission, EllWee AB (listed on Nasdaq First North), JEQ Capital Holding, Corpura Holding, Campingstugan Invest, Black Lion Media Group AB, Glassaparken AB and JJV Invest AB. Alexander has been part of DanCann Pharma's journey from the beginning and has always worked as an advisor for founder and CEO Jeppe Krog Rasmussen. Alexander has great experience when it comes to the financial markets, corporate finance and investor relations.
お知らせ • Sep 21Dancann Pharma A/S Announces Board ChangesDancann Pharma A/S announced that Magnus Østergaard Dahlmann and Per Wester resign from the Board of Directors with effect from 20 September 2022. As a consequence hereof, the Board of Directors proposed election of: Jeppe Krog Rasmussen, Smaragdvej 9, 9 tv. 7100 Vejle Denmark. and Alexander Schoeneck Runnvägen 24, 79153 Falun, Sweden. as new board members (in replacement of Magnus Østergaard Dahlmann and Per Wester). Jeppe Krog Rasmussen and Alexander Schoeneck were elected unanimously and with all votes cast. As from the extraordinary general meeting, the members of the Board of Directors are Carsten Trads, Christian Carlsen, Tue Østergaard, Jeppe Krog Rasmussen and Alexander Schoeneck. The Board of Directors noted that Carsten Trads continues as chairman, and that Christian Carlsen continues as vice-chairman.
Reported Earnings • Sep 02Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr.4.64m (loss widened 161% from 2Q 2021). Over the next year, revenue is forecast to grow 522%, compared to a 6.9% growth forecast for the Pharmaceuticals industry in Germany.
Board Change • Aug 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 16Dancann Pharma A/S Appoints Charlotte Hagedorn Jørgensen as New Head of Quality AssuranceDanCann Pharma A/S announced the employment of Charlotte Hagedorn Jørgensen as Head of Quality Assurance at DanCann Pharma A/S. Charlotte Hagedorn Jørgensen joins the DanCann Pharma team as the Company's Head of Quality Assurance. She is an experienced quality management professional and will oversee implementing relevant quality systems according to global standards such as GMP and GDP. Charlotte Hagedorn Jørgensen has a proven track record within Quality Assurance and joins DanCann Pharma from a job as qualified person at Mezina A/S. She has more than 20 years of experience from working with GMP, GDP and general pharmaceutical issues. Charlotte Hagedorn Jørgensen has on several occasions been the driving force behind startups, which have developed into international successes within the pharma-industry such as 2Care4 ApS. Her entrepreneurial spirit and huge ambitions to make a difference will be a significant asset for DanCann Pharma. She is looking forward to her participation in the development of DanCann Pharma as an important contributor on the Danish and international markets.
Breakeven Date Change • Jun 10Forecast to breakeven in 2024The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests losses will reduce by 42% per year to 2023. The company is expected to make a profit of kr.1.00m in 2024. Average annual earnings growth of 71% is required to achieve expected profit on schedule.
Board Change • May 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Tue Ostergaard was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 12Dancann Pharma A/S Appoints Martin Vedel Ernst as New Chief Financial OfficerDancann Pharma A/S announced that the Company appoints Martin Vedel Ernst as new Chief Financial Officer. In the future, DanCann Pharma's financial tasks will be handled by Martin Vedel Ernst. Martin Ernst has an educational background as Cand. Merc. Aud. from Copenhagen Business School and business experience from jobs as accountant at Deloitte and as Group Financial Controller at Vestas.
Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Christian Carlsen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 28Dancann Pharma A/S Elects Tue Østergaard as New Board MemberDancann Pharma A/S at the annual general meeting held on April 27, 2022 elected Tue Østergaard as a new board member.
お知らせ • Mar 29DanCann Pharma A/S Appoints Sarah Mai Lykke-Kjeldsen as New Chief Operating Officer, Effective 1 April 2022DanCann Pharma A/S announced that the company has appointed Sarah Mai Lykke-Kjeldsen as new Chief Operating Officer. Sarah Mai Lykke-Kjeldsen will join DanCann Pharma on 1 April 2022.
お知らせ • Mar 23Dancann Pharma A/S to Report Fiscal Year 2021 Results on Apr 13, 2022Dancann Pharma A/S announced that they will report fiscal year 2021 results on Apr 13, 2022
お知らせ • Feb 09Dancann Pharma A/S Has Submitted Application to the Danish Medicines Agency for Eu-GMP-Approval for Biotech PharmDanCann Pharma A/S announced that the Company submitted its application for EU-GMP-approval to the Danish Medicines Agency. Biotech Pharm1 is built on best practices from the pharmaceutical industry in combination with advanced environmentally controlled manufacturing technology and vertical cultivation. This means that the selected geneticists are developed in multi-storey systems without the use of soil or other media, but with a specially developed system that adds the required amount of fluid and nutrients.
Breakeven Date Change • Jun 04Forecast to breakeven in 2025The analyst covering Dancann Pharma expects the company to break even for the first time. New forecast suggests the company will make a profit of kr.1.00m in 2025. Average annual earnings growth of 13% is required to achieve expected profit on schedule.